Elite in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)

Dr. Joseph Muenzer

Pediatrics
101 Manning Dr, 
Chapel Hill, NC 
Accepting New Patients
Elite in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Muenzer is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Muenzer is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). His top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A). Dr. Muenzer is currently accepting new patients.

His clinical research consists of co-authoring 65 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 29 articles and participated in 7 clinical trials in the study of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome).

Specialties
Pediatrics
Licenses
Pediatrics in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

101 Manning Dr, Chapel Hill, NC 27599

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: DNL310
Study Phase: Phase 1/Phase 2
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
Enrollment Status: Completed
Publish Date: June 10, 2024
Intervention Type: Other
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Biological
Study Drug: SB-913
Study Phase: Phase 1/Phase 2
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Enrollment Status: Completed
Publish Date: June 28, 2021
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®
A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Other, Behavioral
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

65 Total Publications

Unmet needs in the treatment and care of somatic manifestations in mucopolysaccharidosis type II: A targeted literature review.
Unmet needs in the treatment and care of somatic manifestations in mucopolysaccharidosis type II: A targeted literature review.
Journal: Molecular genetics and metabolism
Published: August 05, 2025
Similar Doctors
Elite in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
Dr. Maria L. Escolar
Pediatrics
Elite in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
Dr. Maria L. Escolar
Pediatrics
1450 Raleigh Rd, Suite 100, 
Chapel Hill, NC 
 (2.1 miles away)
919-966-4135
Languages Spoken:
English
See accepted insurances

Maria Escolar is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Escolar is rated as a Distinguished provider by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). Her top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), and Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome).

Experienced in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
Dr. Elizabeth R. Jalazo
Pediatrics
Experienced in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
Dr. Elizabeth R. Jalazo
Pediatrics

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elizabeth Jalazo is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Jalazo is rated as an Experienced provider by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). Her top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A), Mucopolysaccharidoses (MPS), and Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome). Dr. Jalazo is currently accepting new patients.

Experienced in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
Dr. Zheng J. Fan
Pediatrics | Medical Genetics | Neurology
Experienced in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
Dr. Zheng J. Fan
Pediatrics | Medical Genetics | Neurology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Zheng Fan is a Pediatrics specialist and a Medical Genetics provider in Chapel Hill, North Carolina. Dr. Fan is rated as an Advanced provider by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). Her top areas of expertise are Angelman Syndrome, Obstructive Sleep Apnea, Central Sleep Apnea, and Primary Lateral Sclerosis. Dr. Fan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muenzer's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile